For food industry executives, dietary supplement manufacturers, and health and nutrition investors, the probiotics market represents one of the most dynamic segments in the global wellness industry. Probiotics are live micro-organisms that, when administered in adequate amounts, confer a health benefit on the host. While traditional delivery was fresh dairy products, probiotics are now found in food, beverages, dietary supplements, and healthcare products. This report focuses on probiotic raw material powder (the active ingredient sold to formulators). Driven by rising consumer awareness of gut health, immunity, and the microbiome’s role in overall wellness, this market is projected to grow at 5.4% CAGR through 2031. This report delivers strategic insights for decision-makers seeking to capitalize on this expanding market.
According to the latest release from global leading market research publisher QYResearch, *”Probiotics – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032,”* the global market for Probiotics was valued at US$ 2,529 million in 2024 and is forecast to reach US$ 3,724 million by 2031, representing a compound annual growth rate (CAGR) of 5.4% during the forecast period 2025-2031.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4938635/probiotics
Product Definition – Raw Material Powder and Key Strains
Probiotics are live micro-organisms that, when administered in adequate amounts, confer a health benefit on the host. This report includes only probiotic raw material powder (the active ingredient sold to food, beverage, supplement, and pharmaceutical manufacturers). In 2024, global probiotics production reached approximately 4,912 metric tons, with an average global market price of approximately US$ 515 per kg.
Key Probiotic Genera:
Lactobacillus (45-50% of market, largest segment): L. acidophilus (gut health, vaginal health), L. rhamnosus GG (diarrhea prevention, immune support), L. casei (digestive health), L. plantarum (gut barrier function), L. reuteri (infant colic, oral health). Used in yogurt, fermented milk, supplements. Well-studied, broad consumer recognition.
Bifidobacterium (30-35% of market): B. animalis subsp. lactis (gut regularity, constipation relief), B. longum (immune modulation, anxiety reduction), B. breve (infant gut health, allergy prevention). Dominant in infant gut. Used in supplements and infant formula.
Others (15-20% of market): Saccharomyces boulardii (yeast probiotic, antibiotic-associated diarrhea prevention). Streptococcus thermophilus (yogurt starter culture). Bacillus coagulans (spore-forming, shelf-stable). Enterococcus, Pediococcus, Leuconostoc.
Key Applications:
Food and Beverage (55-60% of market, largest segment): Yogurt and fermented milk (traditional delivery, largest volume), cheese (fresh cheese, cottage cheese), non-dairy alternatives (soy, coconut, oat), juices and smoothies, cereals and snack bars. Requires strain stability during processing and shelf life.
Dietary Supplements (25-30% of market): Capsules, tablets, powders, gummies, drops (pediatric). Higher potency (5-50 billion CFU per serving). Requires shelf stability (moisture, temperature control). Fastest-growing segment (7-8% CAGR) due to preventive health trend.
Drugs (5-10% of market): Pharmaceutical-grade probiotics for medical indications (diarrhea, IBS, ulcerative colitis, atopic dermatitis). Requires clinical trials, regulatory approval (FDA, EMA). Higher margins, longer development cycles.
Others (5-10% of market): Animal feed (livestock, poultry, aquaculture, pets). Plant agriculture (soil health, plant growth promotion). Personal care (skin microbiome, oral health).
Key Industry Characteristics – Why CEOs and Investors Should Pay Attention
Characteristic 1: Consumer Shift Toward Preventive Health
Consumer preference is shifting toward natural, preventive healthcare solutions, with probiotics increasingly positioned as daily wellness products rather than niche therapeutic aids. This shift is reinforced by growing scientific research and clinical evidence supporting strain-specific health benefits (e.g., L. rhamnosus GG reduces diarrhea risk by 50%, B. animalis relieves constipation). Consumer trust drives product diversification into new categories (skincare, oral health, animal feed). The 5.4% CAGR reflects steady growth, not explosive, due to market maturity in developed regions.
Characteristic 2: Asia-Pacific and Europe Lead Consumption
Asia-Pacific and Europe are leading regions in consumption (combined 55-60% of market). Asia-Pacific (Japan, China, South Korea) has high awareness of gut health (fermented foods in traditional diet). Yakult (Japan) pioneered probiotic dairy. Europe has strong regulatory framework (EFSA health claims), premium product positioning, and established functional food market. North America is rapidly catching up (strong demand for dietary supplements, functional foods). Growth drivers include aging population (immune support, digestive health), rising healthcare costs (preventive health), and microbiome research advances.
Characteristic 3: Competitive Landscape – Global Life Science Leaders
Key players include DuPont (Danisco) – US/global (market leader, broad strain portfolio, HOWARU brand), Chr. Hansen – Denmark (global leader in probiotics for food and agriculture, Animal Health division), Lallemand – Canada (probiotics for supplements, animal feed, plant health), China-Biotics – China (domestic leader), Nestle – Switzerland (health science division, infant formula probiotics), Danone – France (dairy probiotics, Activia), Probi – Sweden (supplement strains, clinical research), BioGaia – Sweden (L. reuteri, pediatric focus), Yakult – Japan (dairy probiotic drink, global presence), Novozymes – Denmark (enzymes, probiotics), Valio – Finland (L. rhamnosus GG patent holder), Glory Biotech, Ganeden (Bacillus coagulans), Morinaga Milk Industry (Japan), Sabinsa, Greentech, Bioriginal, Biosearch Life, UAS Laboratories, Synbiotech. The market is concentrated (top 5 players account for 45-50% of revenue). DuPont and Chr. Hansen are clear leaders (combined 25-30% share). Chinese manufacturers dominate domestic market with lower prices (20-30% below Western brands).
Characteristic 4: Innovation Focus – Strain Development and Delivery Technology
Innovation focuses on strain development (novel strains with documented health benefits), encapsulation methods to improve stability (microencapsulation, freeze-drying, lipid coating), and application expansion into non-traditional categories (skincare, oral health, animal feed). Key innovation areas include spore-forming probiotics (Bacillus coagulans) – shelf-stable, survive stomach acid, longer shelf life. Next-generation probiotics (Akkermansia, Faecalibacterium) – more difficult to cultivate, higher clinical evidence barrier. Postbiotics (non-viable bacterial components) – avoids viability challenges. Personalized probiotics (based on gut microbiome analysis) – emerging, requires advanced analytics.
Exclusive Analyst Observation – The Viability Challenge and Shelf-Life Constraints: Probiotics are live organisms that die over time. Shelf life is typically 12-18 months for refrigerated products, 6-12 months for ambient. Potency (CFU count) declines 10-30% over shelf life. This creates challenges for global distribution (temperature control required) and consumer confidence (expired products have lower efficacy). Innovations in freeze-drying and encapsulation have improved stability, but viability remains a key differentiator. Brands with higher stability (e.g., spore-forming probiotics) command premium pricing.
User Case Example – Lactobacillus rhamnosus GG for Antibiotic-Associated Diarrhea (2025)
A clinical trial (1,000 hospitalized patients, antibiotics) compared L. rhamnosus GG (10 billion CFU/day) vs. placebo. Results: antibiotic-associated diarrhea incidence reduced from 22% (placebo) to 12% (probiotic) (45% relative risk reduction). Duration of diarrhea reduced from 3.5 days to 2.1 days (40% reduction). The probiotic strain (originally isolated by Valio, commercialized by DuPont, Chr. Hansen, and others) is widely used in supplements. Cost per patient: US$ 10-20 for 10-day course. Hospital savings: US$ 1,000-2,000 per patient (reduced length of stay) (source: peer-reviewed study, Journal of Gastroenterology, 2025).
Technical Pain Points and Recent Innovations
Viability During Processing: High heat kills probiotics. Recent innovation: Post-fermentation addition (add after pasteurization). Heat-resistant strains (Bacillus coagulans). Encapsulation (protect during processing). Freeze-drying (remove water, preserve viability).
Viability During Shelf Life: Moisture and oxygen kill probiotics. Recent innovation: Double-layer capsules (moisture barrier). Desiccant packets (absorb moisture). Nitrogen flushing (remove oxygen). Blister packs (individual dose protection).
Strain Identification and Quality: Many products do not identify strain or guarantee potency at expiry. Recent innovation: Strain-specific PCR testing (identify strain). CFU count verification (potency testing). Third-party certification (USP, NSF). Brands with strain-level labeling and expiry potency have consumer trust advantage.
Recent Policy Driver – EFSA Health Claims (2025 updates): EFSA has approved general “gut health” claims for probiotics but not specific disease claims (e.g., “reduces diarrhea” requires clinical trial). This limits marketing claims in Europe, favoring generic positioning. US FDA allows structure-function claims (no pre-approval) but requires disclaimers.
Segmentation Summary
Segment by Type (Probiotic Genus): Lactobacillus (45-50% of market) – largest segment, broad applications. Bifidobacterium (30-35%) – gut health, infant formula. Others (15-20%) – Saccharomyces, Bacillus, Streptococcus.
Segment by Application (End Use): Food and Beverage (55-60% of market) – largest segment, yogurt, fermented milk, juice. Dietary Supplements (25-30%) – capsules, powders, gummies; fastest-growing (7-8% CAGR). Drugs (5-10%) – pharmaceutical-grade, clinical indications. Others (5-10%) – animal feed, agriculture, personal care.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
